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Results

Introduction
• Primary brain tumors rank as the #1 cancer in terms
of years of life lost
• Gliomas represent the majority (80%) of brain tumors
and ATRX-deficient gliomas, i.e., astrocytoma, have
the worst prognosis - average six years of survival.
• ATRX-loss gliomas cooccur with IDH-mut, Tp53-mut,
and 1p/19q non-co-deletion.
• Current treatments include surgery, radiation and
chemotherapy with significant side effects, including
high morbidity and mortality.
• ATRX is a globally repressive chromatin remodeler
through complexing with H3.3 and DAXX, depositing
histone groups on chromatin.
• HOX genes are upregulated in developing fetuses to
promote cell proliferation for development of the
hindbrain and somites
• HOX is overexpressed in ATRX deficient gliomas.
• Research into the mechanism of ATRX deficiencies in
these tumors will have great implications for survival.
• HXR9 is small peptide sequence that inhibits
heterodimerization of HOX:PBX, inhibiting cell
proliferation
• HXR9 is potent, clinically effective and blood-brainbarrier permeable peptide
• Our aim is to establish HXR9 validity in promoting
glioma stem cells apoptosis and elucidate the
mechanism of action to better understand the
role of HOX in gliomagenesis

Decrease in S-Phase of cell cycle
upon treatment with HRX9 in
patient derived gliomas

RNA-seq analysis shows increased
expression of HOXA cluster genes in
ATRX deficient gliomas
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High expression of HOXA cluster genes is
associated with poor prognosis in ATRX
deficient gliomas
Fig. 4 HXR9 induces cell cycle arrest by reducing the % of GS5-22 cells in the
synthetic (S)-phase by 4% and 5% (a) and the % of TS603 cells in both the S
and growth 2 (G2) phases by 1.5% and 6% (b), at 5 µM and 20 µM, respectively
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Conclusions
•
•

Methods

Fig. 2 HOX is overexpressed in ATRX-mut, IDH1-mut, 1p/19q non-co-deleted
backgrounds (a) and correlates with lower overall survival (b). * <0.5, ** <0.01, ***<0.001,
****<0.0001

Dose dependent escalation of HXR9
drives patient derived gliomas towards
apoptosis
a

Inhibition of HOXA cluster genes using HRX9
peptide, suggest its translational role in preclinical
setting.
Increase in apoptosis and reduced proliferation in
HXR9 treated gliomas, open opportunity for in-vivo
experiments.

Future Directions
•
•
•
•

I plan to do qPCR to check if the HOX is
suppressed.
I can do western of a wide variety of proteins to
confirm apoptosis.
I can check the global transcriptional profile
through RNA sequencing to detect different
pathways the HXR9 peptide modulates.
I can test HXR9 in TMZ-resistant, CD133+ stem
cell lines.

Acknowledgements
b
Fig. 1 ATRX-deficient cell lines overexpress HOX, suppressing cFOS, an apoptosis
promoting factor. By competitively inhibiting the HOX-PBX complex, HXR9 may
restore caspase-mediated apoptosis. (Made with Biorender.com)

We thank the MD Anderson Flow Core for cell cycle
analysis, Sharvhari Dharmaiah and Jeffrey Ackroyd for
lab introduction, Ben Whitfield and Bhargavi Barathi for
helpful explanations and advice.

References
1) Arunachalam et al. BMC Cancer 2022;22(400)
2) Morgan et al. Oncotarget 2015;8(19)
3) Goncalves et. Nature 2020;77:3797-3821
4) TCGA et al. NEJM 2015;372(26):2481-2498
Table 1 Patient-derived glioma stem cells (GSCs) treated were the GS5-22 and
TS603 cell lines.

Fig. 3 HXR9 increases late apoptosis by 17% (5 µM) and 30% (20 µM) in GS5-22 ATRX-mut (a) and
34% (20 µM) with 2% increase in early apoptosis (5 µM) in TS603 ATRX-wt (b) glioma stem cells
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